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Abstract
Introduction: Cigarette smokers are at increased risk of poor sleep behaviors. However, it is largely 
unknown whether these associations are due to shared (genetic) risk factors and/or causal effects 
(which may be bidirectional).
Methods: We obtained summary-level data of genome-wide association studies of smoking (smok-
ing initiation [n = 74 035], cigarettes per day [n = 38 181], and smoking cessation [n = 41 278]) and 
sleep behaviors (sleep duration and chronotype, or “morningness” [n = 128 266] and insomnia 
[n = 113 006]). Using linkage disequilibrium (LD) score regression, we calculated genetic correla-
tions between smoking and sleep behaviors. To investigate causal effects, we employed Mendelian 
randomization (MR), both with summary-level data and individual-level data (n  =  333 581 UK 
Biobank participants). For MR with summary-level data, individual genetic variants were combined 
with inverse variance–weighted meta-analysis, weighted median regression, MR-Robust Adjusted 
Profile Score, and MR Egger methods.
Results: We found negative genetic correlations between smoking initiation and sleep duration 
(rg = −.14, 95% CI = −0.26 to −0.01) and smoking cessation and chronotype (rg = −.18, 95% CI = −0.31 
to −0.06), and positive genetic correlations between smoking initiation and insomnia (rg = .27, 95% 
CI = 0.06 to 0.49) and cigarettes per day and insomnia (rg = .15, 95% CI = 0.01 to 0.28). MR pro-
vided strong evidence that smoking more cigarettes causally decreases the odds of being a morn-
ing person, (RAPS) and weak evidence that insomnia causally increases smoking heaviness and 
decreases smoking cessation odds.
Conclusions: Smoking and sleep behaviors show moderate genetic correlation. Heavier smoking 
seems to causally affect circadian rhythm and there is some indication that insomnia increases 
smoking heaviness and hampers cessation. Our findings point to sleep as a potentially interesting 
smoking treatment target.
Implications: Using LD score regression, we found evidence that smoking and different sleep 
behaviors (sleep duration, chronotype (morningness), and insomnia) are moderately genetically 
correlated—genetic variants associated with less or poorer sleep also increased the odds of smok-
ing (more heavily). MR analyses suggested that heavier smoking causally affects circadian rhythm 
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(decreasing the odds of being a morning person) and there was some indication that insomnia 
increases smoking heaviness and hampers smoking cessation. Our findings indicate a complex, 
bidirectional relationship between smoking and sleep behaviors and point to sleep as a potentially 
interesting smoking treatment target.
Introduction
Observationally, cigarette smoking is associated with poor sleep. 
Smokers take a longer time to fall asleep and are at higher risk of 
experiencing sleep disturbances.1 Although sleep duration is gener-
ally shorter in smokers, longer than average sleep duration is more 
common too.2,3 One longitudinal study that followed substance naïve 
adolescents into early adulthood found that erratic sleep patterns pre-
dicted smoking initiation.4 In adults, transitioning from “adequate” 
to “inadequate” sleep duration over a period of 5  years predicted 
heavier smoking5 and preexisting insomnia symptoms increased the 
likelihood of relapse after an attempt to quit smoking.6 Chronotype—
being a “morning” versus an “evening” person—has also been linked 
to smoking such that smokers are more likely to be an evening per-
son.7 This is in contrast to evidence suggesting that young adolescents 
with an evening chronotype show a lower odds of smoking initiation 
4–5  years later.4 The observational nature of the studies described 
here precludes strong conclusions about causality. Unraveling the 
nature of the relationship between smoking and poor sleep is import-
ant, given the major health burden that both behaviors pose.8,9
Observational associations between smoking and sleep may 
reflect common risk factors. These could be environmental in nature, 
such as socioeconomic factors,10,11 or genetic—twin and family stud-
ies have reported a moderate-to-high heritability for both smoking 
and sleep.2,12,13 Genome-wide association studies (GWAS) have iden-
tified genetic variants robustly associated with smoking initiation, 
number of cigarettes smoked per day, and smoking cessation,14 and 
more recently, sleep duration and chronotype15 and insomnia.16 This 
knowledge of the genetic architecture of smoking and sleep allows 
us to investigate the degree to which genetic risk for both phenotypes 
overlaps. With linkage disequilibrium (LD) score regression, a gen-
etic correlation between two phenotypes can be calculated such that 
“0” reflects no overlap in genetic risk and “1” reflects that genetic 
risk for both phenotypes is exactly the same.17 Hammerschlag et al.16 
reported sizeable, positive, genetic correlations between smoking 
and insomnia complaints, but whether smoking behavior shows 
genetic overlap with sleep duration and chronotype is still unknown. 
Moreover, genetic correlations may also reflect causal relationships. 
If, for instance, smoking cigarettes causally increases insomnia, then 
genetic variants that underlie vulnerability for smoking will also be 
associated with insomnia.
Causal effects could operate in either direction, from smoking to 
poor sleep (possibly due to nicotine’s stimulating effects) and from 
poor sleep to smoking (such that cigarettes are used as self-medica-
tion against fatigue). A meta-analysis of clinical trials that looked at 
the effectiveness of nicotine patches as an aid to quit smoking found 
that patch users experienced more sleep disturbances than controls. 
The effects were proportional to the strength of the patch, and 
worse when it was left on overnight,18 suggesting that nicotine has a 
causal, negative effect on sleep. This is in line with research showing 
that nicotine can inhibit sleep-promoting neurons, thereby causing 
arousal and changes in electroencephalography sleep waves.19,20 In 
the other direction, smokers who were offered cigarettes or money 
picked cigarettes more often when they were sleep deprived, even 
when the monetary value was greater than that of the cigarette.21 
Finally, animal work has suggested that passive smoking, via an effect 
on gene expression, can alter circadian rhythm (which determines 
chronotype).22 Overall, current findings are mixed and have focused 
on short-term rather than long-term effects. Novel methods are 
needed to fully disentangle the complex relationship between smok-
ing and sleep. To distinguish genetic correlation from causal relation-
ships, Mendelian randomization (MR) analysis can be applied. MR 
infers causality by taking a set of genetic variants robustly associated 
with an exposure variable as a proxy for this exposure and estimat-
ing its causal effect on an outcome variable.23 Potential horizontal 
pleiotropy (genetic variants affecting the outcome directly, not acting 
through the exposure) can be assessed with sensitivity analyses.
In this study, we first calculated genetic correlations between 
smoking (smoking initiation, cigarettes smoked per day, and smok-
ing cessation), and sleep behaviors (sleep duration, chronotype, and 
insomnia) based on summery-level data of large, published GWAS. 
We then employed MR—using individual-level data of 333 581 par-
ticipants of UK Biobank and summary-level data—to test bidirec-
tional, causal effects between smoking and sleep behaviors.
Methods
Data Sources
For LD-score regression and MR with summary-level data (two-
sample MR), we used summary statistics from GWAS on smoking 
initiation (n  =  74 035), cigarettes smoked per day (n  =  38 181), 
and smoking cessation (being a former vs. a current smoker; n = 41 
278) from the Tobacco and Genetics consortium.14 GWAS based on 
the first release of UK Biobank were used for sleep duration (meas-
ured in hours and as undersleeping [≤6 hours vs. 7–8 hours] and 
oversleeping [≥9 hours vs. 7–8 hours]), chronotype (measured on a 
five-point scale with 2 coded as being a “morning person” and −2 
being an “evening person”; n = 128 266),15 and insomnia (usually 
having trouble falling asleep at night or waking up in the middle 
of the night [cases] vs. never or rarely or sometimes having these 
problems [controls]; n = 113 006).16 Where there was evidence for 
causal effects of any of the sleep behaviors on smoking, we sought 
replication using the second release of UK Biobank as the outcome 
sample (n = 241 008 for smoking initiation; n = 67 193 for cigarettes 
per day; n = 107 874 for smoking cessation).
For MR with individual-level data (one-sample MR), we 
obtained data of 333 581 participants of UK Biobank (first + second 
release).24 Details on the UK Biobank sample and quality control of 
the genetic data within the Medical Research Council - Integrative 
Epidemiology Unit are available in the Supplementary Material.
Statistical Analysis
LD-Score Regression
Genetic correlations between smoking and sleep behaviors were 
estimated with LD-score regression.17 This method is based on 
the expected relationship between the degree of LD between sin-
gle nucleotide polymorphisms (SNPs) and the strength of their 
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association with the phenotype in question as derived from GWAS. 
The GWAS estimate for a particular SNP incorporates the effects of 
all other SNPs that are in LD with that SNP. Logically, SNPs that 
are in high LD with many neighboring SNPs have a higher chance 
of tagging a causal genetic variant as compared to SNPs in lower 
LD. From this it follows that SNPs with a higher degree of LD with 
neighboring SNPs show larger test statistics. This information is 
used to compute a genetic correlation between two phenotypes. For 
a more detailed description of LD-score regression, we refer to the 
work of Bulik-Sullivan et al.17
MR With Individual-Level Data
We investigated causal effects of cigarettes smoked per day and 
smoking cessation on sleep behaviors using MR with individual-
level data. Because genetic variants previously associated with 
cigarettes smoked per day and smoking cessation were identified 
in samples of smokers,14 MR analyses investigating causal effects 
of these variables as exposures have to be stratified by smoking 
status. For cigarettes smoked per day, we used the genetic variant 
rs16969968 as instrumental variable—the minor allele of this SNP 
is associated with smoking, on average, one additional cigarette per 
day.25 Analyses were performed in never, former, and current smok-
ers separately. For smoking cessation, we used the genetic variant 
rs3025343 as instrumental variable. The major allele of this variant 
has been associated with a higher odds of being a former versus 
a current smoker.14 Analyses were performed in ever-smokers (cur-
rent + former smokers) and never-smokers separately. Associations 
between the genetic instruments and the exposure variables as well as 
common confounding variables are provided in the Supplementary 
Material (Supplementary Tables 1–7).
MR entailed linear and logistic regression analyses performed 
in STATA. The genetic instrument for the smoking (exposure) vari-
able was the independent variable (coded as 0, 1, or 2 risk alleles) 
whereas the sleep (outcome) variable was the dependent variable. If, 
for instance, the genetic instrument for smoking more cigarettes per 
day predicts sleep problems in smokers, but not in nonsmokers, this 
would suggest a causal effect of smoking on sleep.
Two Sample MR With Summary-Level Data
Next, we investigated causal effects for all other relationships 
between smoking and sleep, using MR with summary-level data.26 In 
this approach, the gene-exposure association and the gene-outcome 
association are obtained from two different samples. Genetic instru-
ments for the exposure variables were selected in the exposure GWAS 
at two levels of significance, first using SNPs reaching genome-wide 
significance (p < 5 × 10−8) and second using a more liberal threshold 
of p less than 1 × 10−5 (independent SNPs were identified by pruning 
on r2 < .001). Gene-outcome associations, for SNPs associated with 
the exposure, were then extracted from the outcome GWAS. When 
SNPs were not available in the outcome GWAS, proxies were used 
(LD R2 > 0.8; identified using online tool SNiPa). A full list of the 
SNPs used in each analysis is provided in Supplementary Table 8.
Analyses were conducted using the R package of MR-Base, a data-
base and analytical platform to perform MR27. Causal estimates were 
calculated using the Wald ratio in case of genetic instruments consist-
ing of a single SNP.26 Where multiple SNPs were available, these were 
combined using inverse variance−weighted fixed effects meta-analysis 
(IVW).28 The IVW estimate is the mean average of the Wald ratios of 
all SNPs, inversely weighted by their standard error. Conveniently, 
two-sample MR allows sensitivity analyses that are more robust to 
horizontal pleiotropy, albeit less powerful. We employed three sen-
sitivity analyses, relying on distinct and contrasting assumptions; 
weighted median regression, MR-RAPS (Robust Adjusted Profile 
Score) and MR-Egger regression. Weighted median regression is able 
to provide a consistent estimate of a causal effect even when up to 
50% of the weight in a polygenic score comes from invalid instru-
ments.29 MR-RAPS is an extension of IVW, which is more robust to 
deviations of the underlying assumptions of MR because it adjusts 
the profile likelihood of the summary data that is used.30 MR-Egger 
regression is a variation of a test used in meta-analyses to assess small 
study bias. It rests on the InSIDE (Instrument Strength Independent 
of Direct Effect) assumption, which means that the strength of the 
instrument should not correlate with the direct effect that the instru-
ment has on the outcome—a much weaker assumption than that 
of no horizontal pleiotropy.31 The intercept of MR-Egger indicates 
whether there is horizontal pleiotropy. To quantify heterogeneity 
between genetic variants and indicate how likely it is that the NOME 
(NO Measurement Error) assumption was violated, the I2 statistic 
was computed. If I2 is less than 0.9 the NOME assumption is likely 
to be violated. In that case, we applied a SIMEX (simulation extrapo-
lation) correction to MR-Egger, which adjusts for bias caused by such 
violation.32 MR-RAPS and MR-Egger were only reported for genetic 
instruments that contained a sufficient number of SNPs (≥10).
Results
The results of LD-score regression are presented as a forest plot in 
Figure  1. We observed a negative correlation between sleep dur-
ation and smoking initiation (rg = −.14, 95% CI = −0.26 to −0.01, 
p  =  .030) and, in agreement with this, a positive genetic correl-
ation between undersleeping and smoking initiation (rg = .26, 95% 
CI = 0.13 to 0.39, p = 7 × 10−5). The strongest correlation we observed 
was between undersleeping and cigarettes per day, (rg =  .42, 95% 
CI = 0.19 to 0.66, p = 3 × 10−4), which, together with the other cor-
relations described here, points to less or poorer sleep being associ-
ated with smoking (more heavily). Finally, we observed a negative 
correlation between chronotype and smoking cessation (rg = −.18, 
95% CI = −0.31 to −0.06, p =  .005), indicating that genetic vari-
ants associated with being a morning person are also associated with 
reduced likelihood of quitting smoking. As reported previously,16 we 
found positive genetic correlations between insomnia and cigarettes 
per day (rg = .27, 95% CI = 0.06 to 0.49, p = .012) and insomnia 
and smoking initiation (rg = .15, 95% CI = 0.009 to 0.28, p = .037). 
There was no clear evidence for genetic correlations between the 
other sleep and smoking behaviors.
MR With Individual-Level Data
The minor allele of rs16969968, which is associated with smok-
ing more cigarettes per day, was strongly associated with a lower 
chronotype score (ie, being more of an “evening” person) in current 
smokers (beta = −.062, 95% CI = −0.084 to −0.039, p = 6.9 × 10−8; 
Table  1). A  weaker effect size, in the same direction, was found 
in former smokers (beta  =  −.016, 95% CI  =  −0.027 to −0.005, 
p = .004). In never-smokers, the effect was in the opposite direction, 
with the smoking increasing allele of rs16969968 being associated 
with being a “morning” person (beta = .011, CI = 0.003 to 0.020, 
p = .01). There was no clear evidence for causal effects of smoking 
heaviness on sleep duration (in hours of sleep or measured as under-
sleeping or oversleeping) or insomnia, nor was there clear evidence 
for causal effects of smoking cessation on sleep behaviors.
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MR With Summary-Level Data
Using MR with summary-level data of published GWAS studies 
on smoking and sleep behaviors, there was no clear evidence for a 
causal influence of smoking initiation on sleep duration, chronotype, 
or insomnia (Table 2).
In the other direction, there was no clear evidence for causal 
effects of sleep duration or chronotype on smoking behavior 
(Table  3). There was weak evidence for insomnia increasing the 
number of cigarettes smoked per day, but only with the genetic 
instrument combining 16 SNPs (IVW beta = 1.21, 95% CI = 0.20 to 
2.22, p = .02). This was confirmed with both the weighted median 
regression (beta  =  1.36, 95% CI  =  −0.10 to 2.81, p  =  .07) and 
MR-RAPS (beta = 1.26, 95% CI = 0.18 to 2.34, p = .02) sensitivity 
methods. Although MR-Egger regression showed no clear evidence 
for a causal effect (beta = −1.95, 95% CI = −6.79 to 2.89, p = .44), 
the Egger intercept indicated no directional pleiotropy (beta = .17, 
95% CI = −0.08 to 0.41, p = .20; Supplementary Table 14), and so 
it is most likely that this analysis was underpowered. There was 
also weak evidence that insomnia causally influences smoking ces-
sation such that having insomnia complaints decreases the odds 
of being a former versus a current smoker (IVW OR = 0.80, 95% 
CI = 0.65 to 0.97, p  =  .02). This was confirmed with MR-RAPS 
(OR = 0.79, 95% CI = 0.64 to 0.97, p = .02) and MR-Egger regres-
sion (OR = 0.31, 95% CI = 0.11 to 0.87, p =  .04). The weighted 
median method showed no clear statistical evidence for a causal 
effect, but did confirm the direction of effect (OR  =  0.86, 95% 
CI = 0.66 to 1.14, p = .30). There was some weak evidence for plei-
otropy from the Egger intercept (OR = 1.05, 95% CI = 0.999 to 
1.11, p = .09; Supplementary Table 14). For all other relationships 
tested, there was no clear evidence for causality.
We attempted to replicate the aforementioned suggestive find-
ings—implying causal effects of insomnia on cigarettes per day 
and smoking cessation—using the second release of UK Biobank 
as the outcome-sample. These analyses showed no clear evidence 
for a causal effect of insomnia on cigarettes smoked per day (IVW 
beta = .05, 95% CI = −0.32 to 0.42, p = .80) and confirmed weak 
evidence for a causal effect of insomnia on smoking cessation (IVW 
beta = .91, 95% CI = 0.84 to 0.98, p = .02; Table 3).
Discussion
We found evidence of moderate genetic correlations between smok-
ing and sleep behaviors. Genetic variants that were associated with 
insomnia also increased the odds of initiating smoking and were 
associated with smoking more cigarettes per day. Consistent with 
this finding, genetic variants that predicted shorter sleep duration 
increased the odds of initiating smoking and smoking more ciga-
rettes per day. Finally, genetic variants that made it more likely to 
be a morning person (chronotype) were associated with a lower 
odds of smoking cessation. Possible causal relationships underlying 
these genetic correlations were tested with MR analyses. Using MR 
with individual-level data, we found compelling evidence that smok-
ing more cigarettes per day decreases the odds of being a morning 
person. MR with summary-level data indicated weak evidence for 
insomnia causally increasing the number of cigarettes smoked and 
decreasing the odds of quitting smoking.
Although a genetic variant that is robustly associated with 
smoking heaviness was associated with a lower likelihood of being 
a morning person in smokers—consistent with a causal effect of 
smoking heaviness on chronotype—this same genetic variant was 
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Figure 1. Forest plot depicting genetic correlations (rg), as calculated with linkage disequilibrium (LD) score regression, between smoking behaviors and sleep 
behaviors.
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associated with a higher likelihood of morningness in never-smokers. 
This suggests that there is pleiotropy, such that the genetic instru-
ment plays a (direct) role in chronotype. However, given that the 
direction of effect in never-smokers is opposite to that in current 
smokers, and in former smokers the effect is in the same direction as 
smokers but less strong, it is unlikely that pleiotropy is driving the 
association we see in smokers. This suggests that previously reported 
observational associations between smoking, nicotine dependence, 
and being an evening person7 may at least in part be explained by 
a causal effect of smoking on chronotype. One explanation for this 
is that the psychoactive properties of nicotine allow individuals to 
stay more alert into the evening.7 There is also evidence from ani-
mal research that both nicotine and nicotinic acetylcholine receptors 
(nAChRs) play a role in the circadian system.22,33 This could explain 
our finding of an association in never-smokers, given that the genetic 
variant, rs16969968, is a missense mutation that causes a functional 
change in the α5 nAChR subunit protein.34
MR with summary-level data provided suggestive evidence that 
insomnia causally increases smoking heaviness. Although the evidence 
was weak, and it was not replicated in a separate, larger outcome 
Table 1. Mendelian Randomization (MR) Analyses With Individual-Level Data, Estimating Causal Effects of Smoking Behaviors (Cigarettes 
per Day and Smoking Cessation) on Sleep Behaviors (Sleep Duration, Chronotype, and Insomnia)
Exposure Outcome Smoking status N Beta/OR (95% CI) p value
rs16969968 (instrument for  
cigarettes per day)
Sleep duration Never 183 333 −0.006 (−0.013 to 0.002) .13
Former 117 743 0.009 (−0.001 to 0.018) .07
Current 33 101 −0.014 (−0.034 to 0.006) .17
Undersleeping Never 170 271 1.01 (0.99 to 1.03) .12
Former 108 096 0.99 (0.97 to 1.01) .24
Current 30 237 1.02 (0.98 to 1.05) .37
Oversleeping Never 141 833 0.99 (0.96 to 1.01) .30
Former 89 716 1.01 (0.98 to 1.05) .41
Current 23 486 0.98 (0.93 to 1.04) .58
Chronotype Never 183 925 0.011 (0.003 to 0.020) .01
Former 118 041 −0.016 (−0.027 to −0.005) .004
Current 33 285 −0.062 (−0.084 to −0.039) 6.9 × 10−8
Insomnia Never 184 184 0.99 (0.98 to 1.01) .38
Former 118 181 1.01 (0.99 to 1.02) .56
Current 33 343 1.00 (0.97 to 1.04) .79
rs3025343 (instrument for 
 smoking cessation)
Sleep duration Never 183 333 −0.007 (−0.018 to 0.003) .18
Ever 117 743 0.005 (−0.009 to 0.018) .52
Undersleeping Never 170 271 1.01 (0.99 to 1.04) .34
Ever 108 096 1.01 (0.98 to 1.04) .47
Oversleeping Never 141 833 0.99 (0.95 to 1.03) .54
Ever 89 716 1.04 (0.99 to 1.09) .11
Chronotype Never 183 925 −0.002 (−0.015 to 0.010) .72
Ever 118 041 0.011 (−0.006 to 0.027) .20
Insomnia Never 183 082 1.01 (0.99 to 1.03) .37
Ever 118 181 1.00 (0.98 to 1.03) .85
For cigarettes per day, coefficients represent the change in outcome per additional minor allele of rs16969968. For smoking cessation, coefficients represent the 
change in outcome per additional major allele of rs3025343. Sleep duration was measured in hours per day. Undersleeping was defined as sleeping ≤6 hours versus 
7–8 hours and oversleeping as ≥9 hours versus 7–8 hours. Chronotype was measured on a five-point scale, with higher scores indicating being more of a “morning 
person” and lower scores more of an “evening person.” Insomnia was measured as usually having trouble falling asleep at night or waking up in the middle of the 
night (cases) versus never or rarely or sometimes having these problems (controls).
Table 2. Two-Sample Mendelian Randomization (MR) Analyses With Summary-Level Data, Estimating Causal Effects of Smoking Initiation 
on Sleep Behaviors (Sleep Duration, Chronotype, and Insomnia)
Exposure Outcome Threshold N SNPs
IVW Weighted median MR-RAPS MR-Egger
Beta/OR  
(95% CI) p
Beta/OR  
(95% CI) p
Beta/OR  
(95% CI) p
Beta/OR  
(95% CI) p
Smoking initiation Sleep duration p < 1 × 10−5 20 −0.01 (−0.04 to 0.02) .61 −0.004 (−0.05 to 0.04) .86 −0.01 (−0.05 to 0.03) .63 0.02 (−0.08 to 0.12) .77
Smoking initiation Undersleeping p < 1 × 10−5 19 1.01 (0.99 to 1.02) .13 1.01 (0.99 to 1.03) .50 1.01 (1.00 to 1.03) .14 1.00 (0.97 to 1.03) .99
Smoking initiation Oversleeping p < 1 × 10−5 19 1.00 (0.99 to 1.01) .92 1.01 (0.96 to 1.03) .36 1.00 (0.99 to 1.01) .93 1.01 (0.96 to 1.06) .63
Smoking initiation Chronotype p < 1 × 10−5 20 0.001 (−0.04 to 0.04) .97 −0.02 (−0.06 to 0.03) .49 −0.003 (−0.04 to 0.04) .90 −0.09 (−0.22 to 0.04) .19
Smoking initiation Insomnia p < 1 × 10−5 20 1.00 (0.92 to 1.08) .99 1.01 (0.91 to 1.12) .82 1.00 (0.93 to 1.08) .99 1.20 (0.96 to 1.51) .13
Coefficients represent the change in outcome per 2.72-fold increase in the prevalence of smoking initiation (due to the log odds nature of the smoking initiation 
data). Sleep duration was measured in hours per day. Undersleeping was defined as sleeping ≤6 hours versus 7–8 hours and oversleeping as ≥9 hours versus 7–8 
hours. Chronotype was measured on a five-point scale, with higher scores indicating being more of a “morning person” and lower scores more of an “evening 
person.” Insomnia was measured as usually having trouble falling asleep at night or waking up in the middle of the night (cases) versus never/rarely or sometimes 
having these problems (controls). CI = confidence interval; IVW = inverse-variance weighted fixed effects-meta-analysis; RAPS = Robust Adjusted Profile Score; 
SNP = single nucleotide polymorphism; OR = odds ratio.
D
ow
nloaded from
 https://academ
ic.oup.com
/ntr/advance-article-abstract/doi/10.1093/ntr/nty230/5144949 by U
niversity Library user on 16 January 2019
Nicotine & Tobacco Research, 2018, Vol. XX, No. XX6
Ta
b
le
 3
. T
w
o
-s
am
p
le
 M
en
d
el
ia
n
 R
an
d
o
m
is
at
io
n
 (
M
R
) A
n
al
ys
es
 w
it
h
 S
u
m
m
ar
y-
Le
ve
l D
at
a,
 E
st
im
at
in
g
 C
au
sa
l E
ff
ec
ts
 o
f 
S
le
ep
 B
eh
av
io
u
rs
 (
S
le
ep
 D
u
ra
ti
o
n
, C
h
ro
n
o
ty
p
e 
an
d
 In
so
m
n
ia
) 
o
n
 
S
m
o
ki
n
g
 B
eh
av
io
rs
 (
S
m
o
ki
n
g
 In
it
ia
ti
o
n
, C
ig
ar
et
te
s 
p
er
 D
ay
, S
m
o
ki
n
g
 C
es
sa
ti
o
n
).
N
 S
N
Ps
W
al
d 
R
at
io
/ I
V
W
W
ei
gh
te
d 
m
ed
ia
n
M
R
-R
A
PS
M
R
-E
gg
er
E
xp
os
ur
e
O
ut
co
m
e
T
hr
es
ho
ld
B
et
a/
O
R
 (
95
%
 C
I)
p
B
et
a/
O
R
 (
95
%
 C
I)
p
B
et
a/
O
R
 (
95
%
 C
I)
p
be
ta
/O
R
 (
95
%
 C
I)
p
Sl
ee
p 
du
ra
ti
on
Sm
ok
in
g 
in
it
ia
ti
on
p<
5 
× 
10
−8
3
1.
12
 (
0.
47
 t
o 
2.
64
)
0.
81
1.
01
 (
0.
51
 t
o 
1.
99
)
0.
97
—
—
—
—
p<
1 
× 
10
−5
23
0.
91
 (
0.
67
 t
o 
1.
25
)
0.
55
0.
92
 (
0.
63
 t
o 
1.
35
)
0.
67
0.
86
 (
0.
62
 t
o 
1.
18
)
0.
35
0.
23
 (
0.
04
 t
o 
1.
42
)
0.
13
Sl
ee
p 
du
ra
ti
on
C
ig
ar
et
te
s 
pe
r 
da
y
p<
5 
× 
10
−8
3
1.
50
 (
−2
.6
1 
to
 5
.6
1)
0.
47
1.
08
 (
−3
.3
6 
to
 5
.5
2)
0.
63
—
—
—
—
p<
1 
× 
10
−5
23
0.
59
 (
−1
.1
9 
to
 2
.3
7)
0.
51
1.
02
 (
−1
.6
1 
to
 3
.6
5)
0.
45
0.
62
 (
−1
.2
3 
to
 2
.4
7)
0.
52
2.
20
 (
−8
.4
6 
to
 1
2.
86
)
0.
69
Sl
ee
p 
du
ra
ti
on
Sm
ok
in
g 
ce
ss
at
io
n
p<
5 
× 
10
−8
3
0.
77
 (
0.
37
 t
o 
1.
58
)
0.
48
0.
77
 (
0.
32
 t
o 
1.
82
)
0.
55
—
—
—
—
p<
1 
× 
10
−5
23
0.
75
 (
0.
54
 t
o 
1.
06
)
0.
10
0.
81
 (
0.
49
 t
o 
1.
35
)
0.
42
0.
74
 (
0.
51
 t
o 
1.
06
)
0.
10
0.
83
 (
0.
10
 t
o 
1.
91
)
0.
87
U
nd
er
sl
ee
pi
ng
Sm
ok
in
g 
in
it
ia
ti
on
p<
1 
× 
10
−5
15
0.
94
 (
0.
40
 t
o 
2.
18
)
0.
88
0.
88
 (
0.
31
 t
o 
2.
51
)
0.
82
0.
93
 (
0.
43
 t
o 
0.
72
)
0.
86
0.
10
 (
0.
00
 t
o 
58
.7
8)
0.
49
U
nd
er
sl
ee
pi
ng
C
ig
ar
et
te
s 
pe
r 
da
y
p<
1 
× 
10
−5
15
3.
64
 (
−1
.6
0 
to
 8
.8
9)
0.
17
3.
38
 (
−3
.9
2 
to
 1
0.
69
)
0.
36
3.
75
 (
−1
.8
5 
to
 9
.3
6)
0.
19
14
.8
0 
(−
15
.5
3 
to
 4
5.
14
)
0.
36
U
nd
er
sl
ee
pi
ng
Sm
ok
in
g 
ce
ss
at
io
n
p<
1 
× 
10
−5
15
1.
21
 (
0.
45
 t
o 
3.
32
)
0.
71
1.
10
 (
0.
28
 t
o 
4.
35
)
0.
90
1.
22
 (
0.
41
 t
o 
3.
62
)
0.
72
0.
58
 (
0.
00
 t
o 
62
6.
77
)
0.
88
O
ve
rs
le
ep
in
g
Sm
ok
in
g 
in
it
ia
ti
on
p<
1 
× 
10
−5
12
0.
80
 (
0.
27
 t
o 
2.
39
)
0.
68
0.
74
 (
0.
16
 t
o 
3.
35
)
0.
69
0.
79
 (
0.
25
 t
o 
0.
92
)
0.
69
6.
46
 (
1.
00
 t
o 
41
.6
3)
0.
08
O
ve
rs
le
ep
in
g
C
ig
ar
et
te
s 
pe
r 
da
y
p<
1 
× 
10
−5
12
3.
26
 (
−4
.4
1 
to
 1
0.
93
)
0.
40
4.
56
 (
−5
.3
4 
to
 1
4.
47
)
0.
40
3.
32
 (
−4
.8
7 
to
 1
1.
52
)
0.
43
2.
91
 (
−7
.9
4 
to
 1
3.
76
)
0.
61
O
ve
rs
le
ep
in
g 
Sm
ok
in
g 
ce
ss
at
io
n
p<
1 
× 
10
−5
12
0.
58
 (
0.
06
 t
o 
6.
11
)
0.
65
1.
10
 (
0.
11
 t
o 
11
.4
4)
0.
94
0.
55
 (
0.
12
 t
o 
2.
53
) 
0.
44
0.
00
3 
(0
.0
0 
to
 1
.2
1)
0.
09
C
hr
on
ot
yp
e
Sm
ok
in
g 
in
it
ia
ti
on
p<
5 
× 
10
−8
8
0.
78
 (
0.
51
 t
o 
1.
19
)
0.
24
0.
75
 (
0.
47
 t
o 
1.
19
)
0.
22
—
—
—
—
p<
1 
× 
10
−5
55
0.
96
 (
0.
81
 t
o 
1.
13
)
0.
60
0.
99
 (
0.
79
 t
o 
1.
25
)
0.
93
0.
96
 (
0.
80
 t
o 
1.
14
)
0.
61
3.
06
 (
1.
96
 t
o 
4.
78
)
8 
× 
10
−6
C
hr
on
ot
yp
e
C
ig
ar
et
te
s 
pe
r 
da
y
p<
5 
× 
10
−8
8
−0
.1
2 
(−
4.
26
 t
o 
4.
02
)
0.
96
−0
.1
0 
(−
3.
85
 t
o 
3.
66
)
0.
96
—
—
—
—
p<
1 
× 
10
−5
55
0.
35
 (
−1
.0
5 
to
 1
.7
5)
 
0.
62
−0
.0
2 
(−
1.
84
 t
o 
1.
81
)
0.
99
0.
36
 (
−1
.1
0 
to
 1
.8
1)
0.
63
0.
86
 (
−3
.7
8 
to
 5
.5
0)
0.
72
C
hr
on
ot
yp
e
Sm
ok
in
g 
ce
ss
at
io
n
p<
5 
× 
10
−8
8
1.
01
 (
0.
61
 t
o 
1.
64
)
0.
99
1.
08
 (
0.
58
 t
o 
2.
03
)
0.
80
—
—
—
—
p<
1 
× 
10
−5
55
0.
84
 (
0.
66
 t
o 
1.
06
)
0.
15
0.
87
 (
0.
62
 t
o 
1.
23
)
0.
43
0.
84
 (
0.
66
 t
o 
1.
07
)
0.
15
1.
25
 (
0.
61
 t
o 
2.
57
)
0.
55
In
so
m
ni
a
Sm
ok
in
g 
in
it
ia
ti
on
p<
5 
× 
10
−8
1
0.
96
 (
0.
55
 t
o 
1.
67
)
0.
89
—
—
—
—
—
—
p<
1 
× 
10
−5
16
0.
92
 (
0.
78
 t
o 
1.
09
)
0.
40
1.
03
 (
0.
83
 t
o 
1.
28
)
0.
79
0.
93
 (
0.
78
 t
o 
1.
11
)
0.
43
1.
04
 (
0.
40
 t
o 
2.
73
)
0.
94
In
so
m
ni
a
C
ig
ar
et
te
s 
pe
r 
da
y
p<
5 
× 
10
−8
1
−1
.5
6 
(−
5.
78
 t
o 
2.
66
)
0.
47
—
—
—
—
—
—
p<
1 
× 
10
−5
16
1.
21
 (
0.
20
 t
o 
2.
22
)
0.
02
1.
36
 (
−0
.1
0 
to
 2
.8
1)
0.
07
1.
26
 (
0.
18
 t
o 
2.
34
)
0.
02
−1
.9
5 
(−
6.
79
 t
o 
2.
89
)
0.
44
p<
1 
× 
10
−5
*
38
0.
05
 (
−0
.3
2 
to
 0
.4
2)
0.
80
−0
.1
8 
(−
0.
68
 t
o 
0.
33
)
0.
50
0.
05
 (
−0
.3
3 
to
 0
.4
3)
0.
80
−0
.0
4 
(−
0.
80
 t
o 
0.
73
)
0.
93
In
so
m
ni
a
Sm
ok
in
g 
ce
ss
at
io
n
p<
5 
× 
10
−8
1
0.
82
 (
0.
34
 t
o 
1.
95
)
0.
66
—
—
—
—
—
—
p<
1 
× 
10
−5
16
0.
80
 (
0.
65
 t
o 
0.
97
)
0.
02
0.
86
 (
0.
66
 t
o 
1.
14
)
0.
30
0.
79
 (
0.
64
 t
o 
0.
97
)
0.
02
0.
31
 (
0.
11
 t
o 
0.
87
)
0.
04
p<
1 
× 
10
−5
*
38
0.
91
 (
0.
84
 t
o 
0.
98
)
0.
02
0.
94
 (
0.
84
 t
o 
1.
05
)
0.
30
0.
91
 (
0.
84
 t
o 
0.
99
)
0.
04
1.
22
 (
0.
99
 t
o 
1.
51
)
0.
07
C
oe
ffi
ci
en
ts
 r
ep
re
se
nt
 th
e 
ch
an
ge
 in
 o
ut
co
m
e 
fo
r 
a 
on
e-
un
it
 in
cr
ea
se
 in
 th
e 
ex
po
su
re
 v
ar
ia
bl
e 
in
 th
e 
ca
se
 o
f c
on
ti
nu
ou
s 
ex
po
su
re
 v
ar
ia
bl
es
 a
nd
 th
e 
ch
an
ge
 in
 o
ut
co
m
e 
pe
r 
2.
72
-f
ol
d 
in
cr
ea
se
 in
 th
e 
pr
ev
al
en
ce
 o
f t
he
 e
xp
os
ur
e 
fo
r 
bi
na
ry
 e
xp
os
ur
e 
va
ri
ab
le
s 
(d
ue
 t
o 
th
e 
lo
g 
od
ds
 n
at
ur
e 
of
 t
he
 b
in
ar
y 
ex
po
su
re
 d
at
a)
. S
le
ep
 d
ur
at
io
n 
w
as
 m
ea
su
re
d 
in
 h
ou
rs
 p
er
 d
ay
. U
nd
er
sl
ee
pi
ng
 w
as
 d
efi
ne
d 
as
 s
le
ep
in
g 
≤6
 h
ou
rs
 v
er
su
s 
7-
8 
ho
ur
s 
an
d 
ov
er
sl
ee
pi
ng
 a
s 
≥9
 h
ou
rs
 v
er
su
s 
7-
8 
ho
ur
s.
 C
hr
on
ot
yp
e 
w
as
 m
ea
su
re
d 
on
 a
 fi
ve
-p
oi
nt
 s
ca
le
, w
it
h 
hi
gh
er
 s
co
re
s 
in
di
ca
ti
ng
 b
ei
ng
 m
or
e 
of
 a
 ‘m
or
ni
ng
 p
er
so
n’
 a
nd
 lo
w
er
 s
co
re
s 
m
or
e 
of
 a
n 
‘e
ve
ni
ng
 p
er
so
n’
. I
ns
om
ni
a 
w
as
 m
ea
su
re
d 
as
 u
su
al
ly
 
ha
vi
ng
 t
ro
ub
le
 f
al
lin
g 
as
le
ep
 a
t 
ni
gh
t 
or
 w
ak
in
g 
up
 in
 t
he
 m
id
dl
e 
of
 t
he
 n
ig
ht
 (
‘c
as
es
’)
 v
er
su
s 
ne
ve
r/
ra
re
ly
 o
r 
so
m
et
im
es
 h
av
in
g 
th
es
e 
pr
ob
le
m
s 
(‘
co
nt
ro
ls
’)
. S
m
ok
in
g 
in
it
ia
ti
on
 w
as
 m
ea
su
re
d 
as
 e
ve
r 
sm
ok
in
g 
ve
rs
us
 n
ev
er
 
sm
ok
in
g.
 S
m
ok
in
g 
ce
ss
at
io
n 
as
 fo
rm
er
 s
m
ok
in
g 
ve
rs
us
 c
ur
re
nt
 s
m
ok
in
g.
 *
 R
ep
lic
at
io
n 
w
it
h 
th
e 
2n
d  r
el
ea
se
 o
f U
K
 b
io
ba
nk
 a
s 
th
e 
ou
tc
om
e-
sa
m
pl
e 
(n
=6
7,
19
3 
fo
r 
ci
ga
re
tt
es
 p
er
 d
ay
 / 
n=
10
7,
87
4 
fo
r 
sm
ok
in
g 
ce
ss
at
io
n)
 in
st
ea
d 
of
 t
he
 T
A
G
 c
on
so
rt
iu
m
 a
s 
th
e 
ou
tc
om
e-
sa
m
pl
e 
(n
=3
8,
18
1 
/ n
=6
7,
19
3,
 r
es
pe
ct
iv
el
y)
.
D
ow
nloaded from
 https://academ
ic.oup.com
/ntr/advance-article-abstract/doi/10.1093/ntr/nty230/5144949 by U
niversity Library user on 16 January 2019
Nicotine & Tobacco Research, 2018, Vol. XX, No. XX 7
sample, it was supported by a considerable genetic correlation between 
insomnia and cigarettes per day (rg = .27). In line with this finding, 
there was weak evidence that insomnia decreases the odds of smoking 
cessation, which did replicate in a separate outcome sample. This is in 
accordance with observational evidence showing that pre-quit insom-
nia symptoms predict smoking cessation failure.6,35,36 One mechanism 
underlying a causal relationship from insomnia to smoking heaviness 
and cessation could be that smokers self-medicate against fatigue with 
cigarettes.21 If smoking cigarettes alleviates the negative consequences 
of insomnia, this could make it harder for smokers with insomnia to 
give up smoking. We did not find similar evidence for causal effects 
of sleep duration (in hours or as undersleeping) on smoking behavior, 
which may seem unexpected. However, insomnia is not necessarily 
characterized by a short total sleep duration37 and individuals with a 
naturally short duration of sleep may not experience fatigue. Our sug-
gestive findings that insomnia causally increases smoking heaviness 
and decreases the odds of quitting can be informative for develop-
ing strategies to improve smoking cessation success. Treatments that 
are currently offered (nicotine-replacement therapies and medications 
such as bupropion or varenicline) are only moderately effective38 and 
insomnia may be a promising novel target that could complement 
existing treatments. This was also highlighted in a recent review art-
icle, which reported extensive conceptual support for sleep therapy as 
an adjunctive treatment for smoking.39
Recently, a study in UK Biobank participants (n  =  498 
208) reported observational associations between smoking and sleep 
behaviors, adjusting for sociodemographic variables, self-reported 
stress, depression, alcohol and coffee consumption, physical activity, 
shift work, and chronotype.3 Current smoking versus never smoking 
was associated with a higher odds of oversleeping (OR = 1.47, 95% 
CI = 1.17 to 1.85) whereas heavy current smoking (>20 cigarettes/
day) versus never smoking was associated with a higher odds of both 
undersleeping (OR = 1.46, 95% CI = 1.15 to 1.87) and oversleep-
ing (OR = 2.85, 95% CI = 1.66 to 4.89). Being a former versus a 
never-smoker was associated with experiencing more sleeplessness 
(OR = 1.10, 95% CI = 1.07 to 1.14).3 The authors did not inves-
tigate associations with chronotype, but instead adjusted for it in 
their main analyses. In this study, we did not find clear evidence for 
associations between smoking and oversleeping but we did confirm 
(genetic) associations between smoking and undersleeping. By also 
performing MR analyses, we added crucial knowledge on the pos-
sible causal nature of these associations, and their direction of effect.
Given the large sample sizes employed for our analyses, a major 
strength to our study is that we had much power to detect small 
effects. By combining multiple methods—LD-score regression, MR 
with individual-level data, and MR with summary-level data—we 
were able to differentiate shared genetic risk factors between smok-
ing and sleep, from possible casual effects. A limitation to our study 
is that for some of the phenotypes (smoking initiation, undersleeping, 
oversleeping) we could only test effects with a genetic instrument that 
included SNPs under the threshold p less than 1 × 10−5. These instru-
ments are less robustly associated with the exposure variable and 
therefore less precise when testing causal effects on an outcome vari-
able. Another limitation is that our measures are based on self-report 
that could have introduced measurement error. Disrupted sleep may 
be a marker for general health, inducing false-positive findings when 
testing causal effects of smoking on sleep (given that smoking deterio-
rates health). However, it is unlikely that this has affected our results 
because we found that smoking influences chronotype but not sleep 
duration and/or insomnia. It should also be noted that the sleep dur-
ation measure includes daytime napping. Individuals who sleep little 
during the night but nap a lot during the day will seemingly have a 
healthy sleep duration. Although naps of ≤30 minutes are not a prob-
lem, longer naps can have negative health effects.40 However, there is 
no clear evidence that sleep disturbances and daytime napping are cor-
related,41 so it is unlikely that this has confounded our results. Finally, 
when interpreting our findings, the multiple testing burden should be 
taken into account, while also considering that some of the tests were 
not independent (eg, the variables undersleeping and sleep duration 
are based on the exact same data).
In summary, our findings suggest that smoking and sleep behav-
iors are genetically correlated and that some of this correlation 
reflects causal effects. Smoking more cigarettes per day seems to 
affect circadian rhythm (shifting it to being more of an “evening per-
son”) whereas in the other direction we found weak evidence that 
insomnia increases smoking heaviness and decreases the odds of suc-
cessfully quitting smoking. These findings increase our knowledge of 
the complex relationship between smoking and sleep and can help 
develop more evidence-based treatments for nicotine dependence by 
focusing on insomnia as a novel treatment target.
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